Ruxolitinib-induced extreme thrombocytosis in a COVID-19 patient
Blood Res
.
2021 Sep 30;56(3):201-202.
doi: 10.5045/br.2021.2020245.
Authors
Víctor Manuel Anguiano-Álvarez
1
,
José Antonio Maza-Larrea
2
,
Francisco Javier Rosado-Hernández
2
,
Gustavo Rojas-Velasco
3
,
Raúl Izaguirre-Ávila
1
Affiliations
1
Department of Hematology, National Institute of Cardiology Ignacio Chávez, Mexico City, Mexico.
2
Department of Pharmacovigilance, National Institute of Cardiology Ignacio Chávez, Mexico City, Mexico.
3
Department of Intensive Care Unit, National Institute of Cardiology Ignacio Chávez, Mexico City, Mexico.
PMID:
34400588
PMCID:
PMC8478626
DOI:
10.5045/br.2021.2020245
No abstract available
Publication types
Letter